Detail akcie Cytek Biosci Rg online

Business Summary: Cytek Biosciences, Inc. is a cell analysis solutions company. The Company is advancing the cell analysis tools by delivering high-resolution, high-content, and high-sensitivity cell analysis utilizing its patented Full Spectrum Profiling (FSP) technology. Its platform includes its core FSP instruments, the Cytek Aurora and Northern Lights systems and the Cytek Aurora CS cell sorter; the Cytek Orion reagent cocktail preparation system; the Enhanced Small Particle (ESP) detection technology; the flow cytometer and imaging products under the Amnis and Guava brands, and reagents, software and service to provide a comprehensive and integrated suite of solutions for its customers. Its Cytek Aurora and Northern Lights systems are used in the study of infectious diseases, immunology, immunotherapy, immuno-oncology, oncology, and drug discovery. The Cytek Orion reagent cocktail preparation system enables researchers to fully automate the preparation of antibody cocktails for flow cytometry.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Cytek Biosciences Inc revenues decreased 3% to $139.4M. Net loss increased 43% to $22.5M. Revenues reflect Academia and government segment decrease of 5% to $56.7M, Biotechnology, pharmaceutical, distributor and CRO segment decrease of 1% to $82.7M, EMEA segment decrease of 21% to $36.3M. Higher net loss reflects General and administrative - Ba increase of 33% to $34.1M (expense).